Pfizer just closed its acquisition of Metsera, a weight-loss dr-g company, for roughly $7 billion. That's on top of the cost-cutting. So they're laying people off to save money while writing billion-dollar checks for pipeline. The patent cliff is real and they need something new. But buying your way out of a problem this big is less strategy and more panic.
There are no replies in this thread yet. Be the first to post a reply below: